07.24.25 -- Investors Create A U.S. Biotech With GLP-1 Assets From China

Executing or skipping an engineering run is a consequential decision for any biopharma or CDMO , and it should be supported by all available data, as well as a thorough risk assessment.

Explore the growing role of highly potent active pharmaceutical ingredients in oncology and Antibody-Drug Conjugates to highlight manufacturing challenges, safety protocols, and opportunities for CDMOs.

Discover how this label-free whole-body QMSI combined with plasma LC-MS/MS can help identify the root causes of limited bioavailability and guide smarter optimization strategies early in development.

You want flexibility in scheduling, contracts, and the entire CDMO relationship. While money can't buy you love, it can go a long way in getting that more flexible partnership.

The rising severity of obesity has amplified a therapeutic need in healthcare. Observe as Dr. Srinivasan Shanmugam discusses the challenges and impacts of GLP-1 analogs.

Reconstructed nasal epithelium and CT-based 3D nasal casts provide more predictive, physiologically relevant models for assessing nasal drug delivery, improving accuracy in formulation development.

Review several challenges in biologics analysis and take a closer look at the advanced tools and methods being utilized to improve biophysical analysis reliability and efficiency.

Witness our established microbiology lab in Ireland, providing expertise, staffing, training, and project management to ensure compliant operations and client success.

Watch to uncover key considerations for developing purification processes for bispecific antibodies and learn about an innovative affinity chromatography technology for purifying any recombinant protein.

A structured approach integrating technical expertise, advanced process solutions, and scalable, flexible infrastructure can address unique development and manufacturing challenges.

Delve into the vast diversity and potential of proteins found in nature using a unique protein platform based on machine learning and design of experiments.

On-site labs with our own personnel offer greater control of samples and timelines, minimizing risk for our customers.

Leverage our proprietary non-viral gene insertion technology, ensuring rapid development timelines and high-yield production, making it an ideal solution for complex biologics.

Utilize advanced studies to assess antimicrobial activity accurately, understand drug-microbe interactions, and evaluate the effectiveness of combination therapies.

We don’t just manufacture sterile injectables — we provide trusted partnership, operational excellence, and a deep commitment to getting life-saving therapies to patients safely, reliably, and on time.

Our drug product services provide a holistic approach to DP development, preventing problems early and producing a product that is fit for purpose.